GRAIL Inc.
Rating
Updated: Sep 7, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for ...
Latest News
17 hours ago · seekingalpha.com
GRAIL: Stock Surges As Market Digests FDA Briefing Docs - I Broadly Concur (Rating Upgrade)GRAIL (GRAL) stock surges >30% as FDA briefing notes on Galleri cancer test signal optimism ahead of the AdCom meeting. Galleri's pivotal studies show high specificity (99.6%), PPV up to 77%, and reduced late-stage diagnoses, but sensitivity remains moderate. I assign GRAL a Buy rating, favoring FDA approval and further upside, yet acknowledge significant revenue, reimbursement, and competitive risks.
19 hours ago · benzinga.com
Low False Positives and High Accuracy: FDA Document Fueling Grail Stock SurgeGrail Inc. (NASDAQ:GRAL) stock is surging on Monday after the FDA staff released an executive summary document related to the company's upcoming adcom for the Galleri multi-cancer early detection (MCED) test.
20 hours ago · reuters.com
Grail rallies as FDA staff flags no major concerns for multi-cancer testThe US FDA's staff reviewers did not raise major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers, sending the company's shares soaring 35% on Monday.
21 hours ago · barrons.com
Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review From FDAThe biotech meets with the Food and Drug Administration this week for premarket approval of its landmark cancer blood test.
8 days ago · seekingalpha.com
GRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptGRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
13 days ago · fool.com
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000The transaction was valued at approximately $672,000. The shares traded represented 3% of the direct equity stake held by the CFO prior to the filing.
18 days ago · fool.com
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer TestFDA approval is crucial for Galleri's adoption by insurers. The company received some good news from the FDA, and a pivotal meeting is coming up for Grail's Galleri test.
19 days ago · prnewswire.com
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
22 days ago · prnewswire.com
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare ConferenceMENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, Sep. 14 at 11:30 a.m.
1 month ago · marketbeat.com
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory MeetingGRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove GRAL